FindTrial
Sign In

JAK1 inhibitor

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Pfizer Inc.,

Conditions

Cutaneous T Cell LymphomaCutaneous T Cell Lymphoma (CTCL)Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal TractLarge Granular Lymphocyte LeukemiaLarge Granular Lymphocytic LeukemiaLymphoma, T-CellMycosis FungoidesNK-LGL Leukemia

Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
RecruitingNCT06716658
Institute of Hematology & Blood Diseases Hospital, ChinaCutaneous T Cell Lymphoma, Cutaneous T Cell Lymphoma (CTCL), Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract +7
Start: 2024-12-25End: 2028-11-15Target: 48Updated: 2025-11-18

Unknown Phase

A phase 1, open-label, non-randomized, 2-period, fixed sequence study to investigate the absorption, metabolism and excretion of [14C-PF-04965842] and to assess the absolute bioavailability and fraction absorbed of PF-04965842 in healthy male subjects using a 14C-microtracer approach.
Active, not recruitingNL-OMON45258
Pfizer Inc.,eczeem auto-immune disease eczema
Start: 2017-07-10Target: 6Updated: 2024-02-28

Related Papers

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia
Blood2025-11-03